mild ischemic stroke
Conditions
Interventions
experimental group:Alternate or interval administration
Standard administration group:Single or combined administration
Sponsors
General Hospital of Shenyang Military Command
Eligibility
Sex/Gender
Male
Inclusion criteria
Inclusion criteria: 1) aged = 18 years; 2) nondisabling ischemic stroke (group NIHSS= 3 points); 3) the onset time is greater than 30 days; 4) signed informed consent.
Exclusion criteria
Exclusion criteria: 1. Bleeding or other pathological brain diseases, such as vascular malformations, tumors, abscesses, or other common non ischemic brain diseases (e.g., multiple sclerosis), were diagnosed according to baseline CT or MRI; 2. There are only separate sensory symptoms (such as numbness), single vision change, separate dizziness or vertigo, but baseline head CT or MRI no evidence of ischemic stroke; 3. MRS>2 score (medical history before onset) in groups; 4. NIHSS= 11 points in groups; 5. There are definite indications for anticoagulation (suspected of cardiac embolism, such as atrial fibrillation, known prosthetic heart valves, suspicious endocarditis, etc.); 6. The use of heparin or oral anticoagulant drugs within ten days before groups; 7. Contraindications to the use of clopidogrel and aspirin; 8. Have a history of intracranial bleeding or have a history of amyloid cerebrovascular disease; 9. History of asthma or COPD (chronic obstructive pulmonary disease); 10. High-risk, slow arrhythmia, such as sick sinus syndrome, two or three degree atrioventricular block, no pacemaker related bradycardia, syncope; 11. Uric acid nephropathy history; 12. It is expected that nonsteroidal anti-inflammatory drugs other than aspirin may be used for long periods (>7 days); 13. Had a history of gastrointestinal bleeding within 3 months, or had undergone major surgery within 30 days before groups; 14. Angioplasty / vascular surgery for light stroke /TIA; 15. Domestic surgery or endovascular treatment is expected within the next 3 months; 16. Other surgical or interventional treatments may require termination of the test; 17. Suffer from severe non cardiovascular and cerebrovascular diseases, and the expected survival time is less than 12 months; 18. Women who have not taken effective contraceptive measures, who have positive pregnancy tests, and women who are pregnant or are lactating; 19. Undergoing an experimental drug or instrument test; 20. Have participated in other clinical drug research in the past 30 days; 21. Mental illness, cognitive or emotional disorders cannot be understood and or subject to research procedures and follow-up; 22. Hematocrit <30%; 23. Polymorphisms in the COX1 and CYP2C19 genes suggest slow metabolism.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Platelet function; | — |
Countries
China
Contacts
Public ContactChen Huisheng
General Hospital of Shenyang Military Command
Outcome results
None listed